CX-839-004: A phase I/II study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 combined with nivolumab in patients with renal cell carcinoma, melanoma, and non-small cell lung cancer Meeting Abstract
| Authors: | Lam, E.; Tannir, N. M.; Meric-Bernstam, F.; Vaishampayan, U.; Orford, K. W.; Molineaux, C.; Gross, M.; MacKinnon, A.; Voss, M. |
| Abstract Title: | CX-839-004: A phase I/II study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 combined with nivolumab in patients with renal cell carcinoma, melanoma, and non-small cell lung cancer |
| Meeting Title: | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 4 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Nov 9-13 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2016-11-16 |
| Start Page: | 82 |
| Language: | English |
| DOI: | 10.1186/s40425-016-0172-7 |
| PROVIDER: | manual |
| PMCID: | PMC5123387 |
| Notes: | Meeting Abstract: P161 |
